TopFunds

AbbVie Inc.

NYSE: ABBV

Stock price

285.42 USD

(+0%) TODAY

Drug Manufacturers - General
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
3.1
3.6
3.3
3.7
5.3
2.7
6.5
6.6
2.7
2.4
2.4
(2.7)%
02Free cash flow per share
4.3
4
5.9
8.3
8.6
10
12.4
13.6
12.4
10.1
10
8.9%
03Dividends per share
2
2.3
2.6
3.6
4.3
4.7
5.2
5.6
5.9
6.2
6.6
12.5%
04Dividends payout, %
64%
62.4%
77.4%
98.1%
80.8%
1.7%
80.2%
84.9%
2.2%
2.6%
2.8%
(27)%
PROFIT AND LOSS STATEMENT
05Revenue
22,859
25,638
28,216
32,753
33,266
45,804
56,197
58,054
54,318
56,334
61,160
10.3%
06% Change
-
-
-
-
-
-
-
-
-
-
-
10.3%
07Cost of revenue
(4,500)
(5,833)
(7,040)
(7,718)
(7,439)
(15,387)
(17,446)
(17,414)
(20,415)
(16,904)
(18,204)
15%
08Gross profit
18,359
19,805
21,176
25,035
25,827
30,417
38,751
40,640
33,903
39,430
42,956
8.9%
09% Margin
80.3%
77.3%
75.1%
76.4%
77.6%
66.4%
69%
70%
62.4%
70%
70.2%
72.3% A
10Operating expenses
(10,822)
(10,466)
(11,629)
(18,652)
(12,844)
(19,054)
(20,827)
(22,523)
(21,146)
(30,293)
(22,865)
7.8%
11% of Revenue
(47.3)%
(40.8)%
(41.2)%
(57)%
(38.6)%
(41.6)%
(37.1)%
(38.8)%
(38.9)%
(53.8)%
(37.4)%
(43)% A
12Operating Income
7,537
9,340
9,545
6,383
12,983
11,363
17,924
18,117
12,757
9,137
20,091
10.3%
13Income tax expense
(1,501)
(1,931)
(2,418)
(490)
(544)
(1,224)
(1,440)
(1,632)
(1,377)
(570)
(2,364)
4.7%
14Net Income
5,144
5,953
5,309
5,687
7,882
4,616
11,542
11,836
4,863
4,278
4,226
(2)%
15% Margin
22.5%
23.2%
18.8%
17.4%
23.7%
10.1%
20.5%
20.4%
9%
7.6%
6.9%
16.4% A
16Shares Outstanding
1,637
1,631
1,603
1,546
1,484
1,673
1,777
1,778
1,773
1,773
1,774
0.8%
17EPS Basic
3.2
3.7
3.3
3.7
5.3
2.7
6.5
6.7
2.7
2.4
2.4
(2.8)%
18EPS Diluted
3.1
3.6
3.3
3.7
5.3
2.7
6.5
6.6
2.7
2.4
2.4
(2.7)%
19EBITDA
8,200
10,120
10,378
8,310
12,227
12,323
23,933
24,174
17,172
14,910
17,629
8%
% Margin
35.9%
39.5%
36.8%
25.4%
36.8%
26.9%
42.6%
41.6%
31.6%
26.5%
28.8%
33.8% A
20Net Interest Income (expense)
(686)
(965)
(1,004)
(1,144)
(1,509)
(2,280)
(2,384)
(2,044)
(1,684)
(2,160)
(2,627)
14.4%
21Net Debt / EBITDA
2.8
3.1
2.7
4
2.2
6.4
2.8
2.3
2.8
4.2
3.6
3.4 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
8,399
5,100
9,303
7,289
39,924
8,449
9,746
9,201
12,814
5,524
5,229
(4.6)%
23Short-term investments
8
1,323
486
772
-
30
84
28
2
31
28
13.4%
24Accounts receivable
4,730
4,758
5,088
5,384
5,428
8,822
9,977
11,254
11,155
10,919
12,589
10.3%
25Other current assets
1,458
3,562
4,741
1,895
2,354
3,562
4,993
4,401
4,932
4,927
6,265
15.7%
26Inventory
1,719
1,444
1,605
1,605
1,813
3,310
3,128
3,579
4,099
4,181
4,951
11.2%
27Total Current Assets
16,314
16,187
21,223
16,945
49,519
24,173
27,928
28,463
33,002
25,582
29,062
5.9%
Non-Current Assets
28Net property, plant & equipment
2,565
2,604
2,803
2,883
2,962
5,248
5,110
4,935
4,989
5,134
6,365
9.5%
29Long-term investments
145
1,783
2,090
1,420
93
293
277
241
304
279
299
7.5%
30Other non-current assets
34,026
45,525
44,670
38,104
36,541
120,851
113,214
105,166
96,416
104,166
98,234
11.2%
31Total Non-Current Assets
36,736
49,912
49,563
42,407
39,596
126,392
118,601
110,342
101,709
109,579
104,898
11.1%
Total Assets
53,050
66,099
70,786
59,352
89,115
150,565
146,529
138,805
134,711
135,161
133,960
9.7%
LIABILITIES
Current Liabilities
32Accounts payable
1,597
1,407
1,474
1,546
1,452
2,276
2,882
2,934
3,688
2,945
3,592
8.4%
33Short-term debt
2,431
402
6,415
5,308
3,753
8,677
12,673
4,302
7,191
6,804
8,749
13.7%
34Other current liabilities
6,866
7,972
8,752
10,385
10,380
17,708
19,639
22,302
26,962
29,000
30,948
16.3%
35Total Current Liabilities
10,894
9,781
16,641
17,239
15,585
28,661
35,194
29,538
37,841
38,749
43,289
14.8%
Non-Current Liabilities
36Long-term debt
29,240
36,440
30,953
35,002
63,246
78,386
64,902
59,889
52,929
61,060
60,319
7.5%
37Other non-current liabilities
8,971
15,242
18,095
15,557
18,456
30,421
30,997
32,091
33,544
31,988
33,580
14.1%
38Total Non-Current Liabilities
38,211
51,682
49,048
50,559
81,702
108,807
95,899
91,980
86,473
93,048
93,899
9.4%
39Total Liabilities
49,105
61,463
65,689
67,798
97,287
137,468
131,093
121,518
124,314
131,797
137,188
10.8%
SHAREHOLDERS` EQUITY
40Common stock
17
18
18
18
18
18
18
18
18
18
18
0.6%
41Retained earnings / (deficit)
2,248
4,378
5,459
3,368
4,717
1,055
3,127
4,784
(1,000)
(7,900)
(15,493)
-
42Accumulated other comprehensive income / (loss)
(2,561)
(2,586)
(2,727)
(2,480)
(3,596)
(3,117)
(2,899)
(2,199)
(2,305)
(1,925)
(1,144)
(7.7)%
43Noncontrolling interests
-
-
-
-
-
21
28
33
37
39
42
-
44Total shareholders' equity
3,945
4,636
5,097
(8,446)
(8,172)
13,097
15,436
17,287
10,397
3,364
(3,228)
-
45Total Liabilities and shareholders' Equity
53,050
66,099
70,786
59,352
89,115
150,565
146,529
138,805
134,711
135,161
133,960
9.7%
46Total Debt
31,671
36,842
37,368
40,310
67,088
87,063
77,575
64,191
60,120
67,841
69,068
8.1%
47Net Debt
23,272
31,742
28,065
33,021
27,164
78,614
67,829
54,990
47,306
62,317
63,839
10.6%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
5,144
5,953
5,309
5,687
7,882
4,616
11,542
11,836
4,863
4,278
4,226
(2)%
49Depreciation & amortization
836
1,189
1,501
1,765
2,017
6,471
8,521
8,467
8,698
8,386
8,139
25.6%
50Share-based compensation expense
282
353
365
421
430
753
692
671
747
911
955
13%
51Changes in working capital and other assets
1,273
(454)
2,785
5,554
2,995
5,748
2,022
3,969
8,531
5,231
5,710
16.2%
52Net cash flows from operating activities
7,535
7,041
9,960
13,427
13,324
17,588
22,777
24,943
22,839
18,806
19,030
9.7%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(532)
(479)
(529)
(638)
(552)
(798)
(787)
(695)
(777)
(974)
(1,214)
8.6%
54Purchases of investments / marketable securities
(851)
(5,315)
(2,230)
(1,792)
(583)
(61)
(119)
(1,438)
(77)
(73)
(35)
(27.3)%
55Proceeds from maturities of marketable securities
880
2,359
2,793
2,160
2,699
1,525
98
1,530
55
555
76
(21.7)%
56Other investing activities
(12,433)
(2,639)
(308)
(736)
(968)
(38,223)
(1,536)
(20)
(1,210)
(20,328)
(5,470)
(7.9)%
57Net cash flows from investing activities
(12,936)
(6,074)
(274)
(1,006)
596
(37,557)
(2,344)
(623)
(2,009)
(20,820)
(6,643)
(6.5)%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(7,586)
(6,033)
(1,410)
(12,014)
(629)
(978)
(934)
(1,487)
(1,972)
(1,708)
(808)
(20.1)%
59Dividends paid, net
(3,294)
(3,717)
(4,107)
(5,580)
(6,366)
(7,716)
(9,261)
(10,043)
(10,539)
(11,025)
(11,657)
13.5%
60Debt issuance (repayments), net
16,623
5,594
(2)
3,229
26,247
(2,683)
(8,414)
(12,433)
(4,149)
7,350
(327)
-
61Other financing activities
9
228
7
(31)
(544)
(124)
(430)
(840)
(562)
172
68
22.4%
62Net cash flows from financing activities
5,752
(3,928)
(5,512)
(14,396)
18,708
(11,501)
(19,039)
(24,803)
(17,222)
(5,211)
(12,724)
-
63Increase (decrease) in cash and cash equivalents
51
(3,299)
4,203
(2,014)
32,635
(31,475)
1,297
(545)
3,613
(7,290)
(295)
-
64Cash and equivalents, ending balance
8,399
5,100
9,303
7,289
39,924
8,449
9,746
9,201
12,814
5,524
5,229
(4.6)%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
7,003
6,562
9,431
12,789
12,772
16,790
21,990
24,248
22,062
17,832
17,816
9.8%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

AbbVie Inc. (ABBV) financial statements and performance

Explore AbbVie Inc. (ABBV) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.